|RxNews Recap for Thursday 12-03-09|
|By Mary Davila|
|Thursday, 03 December 2009 18:43|
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.
Access Pharmaceuticals, Inc., (OTC Bulletin Board:ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.
Alkermes, Inc. (NASDAQ: ALKS) and Acceleron Pharma, Inc. today announced that Alkermes has licensed a proprietary long-acting Fc fusion technology platform, called the Medifusion™ technology, which is designed to extend the circulating half-life of proteins and peptides.
Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced the launch of an international registry designed to address the urgent need to better understand treatment patterns and outcomes for patients with peripheral T-cell lymphoma (PTCL).
AdvanSource Biomaterials Corporation (NYSE Amex: ASB), a leading developer of advanced polymer materials for a broad range of medical devices, today announced it will be exhibiting at the 3rd Annual BIOMEDevice Exposition being held at the McEnery Convention Center in San Jose, California, from December 9-10, 2009.
Biogen Idec Inc. (NASDAQ:BIIB) today announced that it has increased its offer to purchase all of the outstanding shares of Facet Biotech Corporation (NASDAQ: FACT) to $17.50 per share in cash, representing an increase of $3.00 per share, or 21%, over its previous offer.
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the early closing of enrollment in its ecallantide Phase 2 program. Ecallantide, in development as therapy to reduce bleeding in on-pump cardiac surgery, is now known as CB-500,929.
Celsion Corporation (NASDAQ:CLSN), a leading oncology drug development company, today provided an update on the progress of its pivotal ThermoDox® Phase III "HEAT” trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer.
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today that its Board of Directors has authorized the repurchase of up to $50 million of its outstanding shares of common stock in order to return value to its shareholders.
Genzyme Corporation (Nasdaq: GENZ) announced today that it will reopen enrollment in the Alglucosidase Alfa Temporary Access Program (ATAP), a program which provides access to treatment for severely affected adults with Pompe disease prior to commercial approval of Lumizyme™ (alglucosidase alfa).
GP Strategies Corporation (NYSE: GPX), announced that its principal operating subsidiary, global performance improvement solutions provider General Physics Corporation, has acquired Option Six, Inc., a provider of custom courseware development with expertise in the software and pharmaceutical industries.
Helicos BioSciences Corporation (NASDAQ: HLCS) announced today that, as previously disclosed, it has posted a presentation on its website regarding the advantages of Helicos’ single molecule sequencing technology in clinical diagnostics.
IsoRay, Inc. (Amex: ISR) announced today that it has signed a distribution agreement with Oncura to distribute the I-125 brachytherapy seed, OncoSeed™.
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, today announced that the Company will hold a conference call at 8:00 a.m. ET on Monday, December 14, 2009, to review the clinical data reported on TAP compounds at the AACR-NCI-EORTC, American Society of Hematology, and San Antonio Breast Cancer Symposium medical meetings held in November/December 2009.
Jazz Pharmaceuticals, Inc. (Nasdaq:JAZZ) announced today that Kathryn E. Falberg has been appointed Senior Vice President and Chief Financial Officer.
Kyto Biopharma Inc. (OTCBB: KBPH), is a biotechnology company focused on developing monoclonal antibody and oligonucleotide targeting therapeutics based on a proprietary vitamin B12 platform for the treatment of various forms of cancer.
Mannatech, Incorporated (NASDAQ:MTEX), a global pioneer in the development of high-quality health, wellness, skin care and weight and fitness solutions based on nutritional science, announced today that President and CEO Wayne L. Badovinus has resigned from the company for personal reasons as its top executive and Board member.
Neurologix, Inc. (OTCBB:NRGX), a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced the completion of all planned surgeries in an ongoing Phase 2 clinical trial of the company’s gene transfer approach to the treatment of advanced Parkinson’s disease.
NeoPharm, Inc. (Other OTC: NEOL.PK), announced today that it has reached a settlement agreement with Diosynth, RTP (“Diosynth”).
Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it will be hosting an online webinar on December 10, 2009, at 9PM ET to discuss current progress with Cobroxin and Nyloxin Rx, the Company’s treatments for chronic pain.
NovaDel Pharma Inc. (NYSE AMEX:NVD) notified NYSE Amex LLC (“Exchange”) of its intent of voluntarily delist its common stock from the Exchange.
OncoVista Innovative Therapies, Inc. (OTCBB:OVIT) announced today that its application for reinstatement on the Over-The-Counter Bulletin Board has been accepted.
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, initially intended to treat chronic and acute wounds, today unveiled an expanded regulatory/commercial pipeline for its Microcyn-based products as preparation for the company’s CEO and founder, Hoji Alimi, to provide even greater detail at the OneMedForum on January 12, 2010 in San Francisco.
Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that its collaboration partner, Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA (SIX:COPN), has completed enrollment of 514 patients in the European Phase III clinical trial to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis.